LinkedIn post from Kari Sarvanto outlines CRB's systems-level oncology approach and its lead candidate, CRB091, aiming to restore cellular regulation rather than kill cancer cells.
Key Takeaways
- CRB is developing CRB091 as a non-cytotoxic, systems-level oncology candidate
- Preclinical data reported include reduced cancer cell viability in vitro
- No meaningful toxicity observed to date and reported synergistic effects beyond individual